AIM-listed Accumuli, which provides IT security and risk management services, swung to a pre-tax annual loss but hiked its dividend by 15%, saying that its outlook and growth prospects remain strong.
Losses before tax from continuing operations totalled £0.9m in the year to March 31st, compared with a profit of £0.3m the year before, reflecting the costs associated with its "buy and build strategy".
However, the gross profit increased by 32% to £9.9m, from £7.5m the year before, on revenues that grew 18% to £16.6m.
The company said it produced "another excellent performance" during a period which involved a number of acquisitions and a "re-organisation" of the business.
Acquisitions made during the year contributed 23% of group revenues and 29% to gross profit.
The group gross margin increased to 60% from 53% the year before, due to the shift in mix towards service-led revenues.
Accumuli proposed a dividend of 0.46p a share, compared with 0.4p last year.
"I am pleased to report on what has been another period of growth and transformation for the business," said Chairman Nick Kingsbury.
"We believe that our continued focus on delivering a wider range of solutions across our growing customer base, combined with targeted acquisitions, leaves us well placed for further growth."
Medical diagnostics company Omega reported a surge in full-year adjusted pre-tax profit after a robust performance from its food intolerance division and said it remains positive about future trading.
Adjusted pre-tax profit soared 41% to £1.10m for the year ended March 31st while turnover firmed 3% to £11.6m. The Scotland-based group said it was encouraged by prospects for its Visitect CD4 HIV testing kit which is now well into its field trials.
Adjusted earnings per shares
fell to 1.2p from 1.3p previously. Gross profit for the period rose 5% to £7.4m.
Among its main divisions, Food Intolerance revenue rose 18% to £5.18m, Allergy and autoimmune revenue slipped 5% to £3.96m while Infectious disease/other revenue dropped 10% to £2.45m.
Chairman David Evans said: "Our future landscape is brightened, as well as dominated, by the prospects for our Visitect CD4 test, which is now well into its field trials. However, we all have a dislike for complete uncertainty and that is our challenge in being able to set our budgets for the current year in relation to both the timing and quantum of CD4 revenues.
"We will make significant progress this year in terms of gaining market acceptance for CD4 and I believe the prospects for the group remain positive."